Insider Trade: Nektar Therapeutics (NKTR)’s director Robert Chess Sold 25,000 shares; Ardsley Advisory Partners Decreased Its Green Plains (GPRE) Holding

Green Plains Inc. (NASDAQ:GPRE) Logo

Ardsley Advisory Partners decreased Green Plains Inc (GPRE) stake by 47.06% reported in 2017Q4 SEC filing. Ardsley Advisory Partners sold 265,900 shares as Green Plains Inc (GPRE)’s stock rose 0.90%. The Ardsley Advisory Partners holds 299,100 shares with $5.04M value, down from 565,000 last quarter. Green Plains Inc now has $661.04 million valuation. The stock decreased 1.67% or $0.27 during the last trading session, reaching $16.15. About 316,983 shares traded. Green Plains Inc. (NASDAQ:GPRE) has declined 25.55% since April 10, 2017 and is downtrending. It has underperformed by 37.10% the S&P500.

Analysts await Green Plains Inc. (NASDAQ:GPRE) to report earnings on May, 7. They expect $-0.23 EPS, down 155.56% or $0.14 from last year’s $-0.09 per share. After $-0.16 actual EPS reported by Green Plains Inc. for the previous quarter, Wall Street now forecasts 43.75% negative EPS growth.

Ardsley Advisory Partners increased Cigna Corporation (NYSE:CI) stake by 2,500 shares to 6,000 valued at $1.22 million in 2017Q4. It also upped Sunrun Inc stake by 480,200 shares and now owns 845,200 shares. Darling Ingredients Inc (NYSE:DAR) was raised too.

Since February 26, 2018, it had 0 insider purchases, and 1 insider sale for $134,883 activity. MAPES MICHELLE sold $134,883 worth of stock or 7,000 shares.

Among 16 analysts covering Green Plains Renewable Energy (NASDAQ:GPRE), 15 have Buy rating, 0 Sell and 1 Hold. Therefore 94% are positive. Green Plains Renewable Energy had 29 analyst reports since July 21, 2015 according to SRatingsIntel. Bank of America initiated Green Plains Inc. (NASDAQ:GPRE) rating on Tuesday, July 21. Bank of America has “Buy” rating and $22 target. The firm has “Buy” rating by Roth Capital given on Tuesday, October 24. The rating was initiated by Robert W. Baird with “Outperform” on Tuesday, July 21. Barclays Capital initiated Green Plains Inc. (NASDAQ:GPRE) on Tuesday, July 21 with “Overweight” rating. BB&T Capital initiated the stock with “Buy” rating in Thursday, November 19 report. The firm has “Buy” rating given on Tuesday, October 17 by Jefferies. The stock has “Neutral” rating by Goldman Sachs on Thursday, August 13. The stock of Green Plains Inc. (NASDAQ:GPRE) earned “Buy” rating by Jefferies on Friday, September 15. Credit Suisse initiated the shares of GPRE in report on Tuesday, July 21 with “Outperform” rating. Credit Suisse maintained it with “Outperform” rating and $27 target in Wednesday, November 18 report.

Investors sentiment decreased to 1.06 in 2017 Q4. Its down 0.18, from 1.24 in 2017Q3. It is negative, as 23 investors sold GPRE shares while 40 reduced holdings. 28 funds opened positions while 39 raised stakes. 42.63 million shares or 4.31% less from 44.55 million shares in 2017Q3 were reported. Commonwealth Of Pennsylvania Pub School Empls Retrmt Sys holds 15,550 shares. California State Teachers Retirement owns 62,042 shares or 0% of their US portfolio. California Employees Retirement Systems invested in 229,906 shares. Teacher Retirement Of Texas holds 0% in Green Plains Inc. (NASDAQ:GPRE) or 13,518 shares. Price T Rowe Assocs Md reported 10,800 shares. Adams Asset Advsrs Limited Com holds 0.12% of its portfolio in Green Plains Inc. (NASDAQ:GPRE) for 59,630 shares. State Of Tennessee Treasury Department has invested 0% in Green Plains Inc. (NASDAQ:GPRE). Suntrust Banks Incorporated accumulated 10,547 shares or 0% of the stock. Ls Advisors Llc, Michigan-based fund reported 1,035 shares. State Teachers Retirement Sys accumulated 0% or 23,354 shares. Millennium Mgmt Limited Liability Company owns 481,009 shares. Numeric Lc holds 0% or 25,400 shares. Citadel Advisors Limited Liability Corp reported 60,031 shares stake. Manufacturers Life Ins The reported 0% in Green Plains Inc. (NASDAQ:GPRE). State Board Of Administration Of Florida Retirement stated it has 29,463 shares.

Investors sentiment decreased to 1.19 in Q4 2017. Its down 0.21, from 1.4 in 2017Q3. It is negative, as 18 investors sold Nektar Therapeutics shares while 82 reduced holdings. 65 funds opened positions while 54 raised stakes. 150.36 million shares or 1.08% more from 148.76 million shares in 2017Q3 were reported. Hanson Mcclain holds 755 shares. Moreover, Baker Bros Advsr Ltd Partnership has 0.09% invested in Nektar Therapeutics (NASDAQ:NKTR) for 171,934 shares. Fny Managed Accounts Limited Liability Company reported 56 shares. D E Shaw And stated it has 0% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Pointstate Cap Lp reported 2.28% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Ls Inv Ltd Company reported 0.02% in Nektar Therapeutics (NASDAQ:NKTR). Renaissance Techs has 0.01% invested in Nektar Therapeutics (NASDAQ:NKTR) for 91,848 shares. Geode Capital Ltd Limited Liability Company reported 1.45M shares or 0.03% of all its holdings. 1492 Mgmt Limited Liability Corporation holds 0.82% or 17,542 shares in its portfolio. Macquarie Grp Incorporated Ltd reported 0% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Brinker Cap Incorporated holds 20,557 shares. Advisory Services Net stated it has 0% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Sabby stated it has 20,000 shares or 0.11% of all its holdings. Louisiana State Employees Retirement invested in 0.18% or 67,700 shares. Wellington Management Grp Llp has invested 0.03% in Nektar Therapeutics (NASDAQ:NKTR).

Among 9 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics has $125 highest and $16 lowest target. $67’s average target is -35.85% below currents $104.45 stock price. Nektar Therapeutics had 25 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, July 18 by J.P. Morgan. The firm has “Buy” rating given on Monday, September 21 by Roth Capital. On Monday, April 2 the stock rating was reinitiated by H.C. Wainwright with “Buy”. Jefferies maintained it with “Buy” rating and $23.0 target in Wednesday, October 18 report. The rating was maintained by Mizuho on Friday, April 6 with “Buy”. On Tuesday, November 8 the stock rating was initiated by Aegis Capital with “Buy”. The rating was maintained by Roth Capital on Wednesday, August 30 with “Buy”. The rating was maintained by Jefferies with “Buy” on Wednesday, August 16. The firm has “Buy” rating by Canaccord Genuity given on Thursday, November 9. The rating was maintained by Piper Jaffray on Thursday, January 7 with “Overweight”.

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. The company has market cap of $16.81 billion. The Company’s product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. It currently has negative earnings. The firm offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A.

Since December 13, 2017, it had 0 buys, and 11 insider sales for $40.88 million activity. ROBIN HOWARD W sold $4.64M worth of Nektar Therapeutics (NASDAQ:NKTR) on Wednesday, December 13. The insider Nicholson John sold 4,879 shares worth $404,664. KUEBLER CHRISTOPHER A sold 40,000 shares worth $3.90 million. $238,453 worth of stock was sold by Hora Maninder on Friday, February 16. $288,382 worth of Nektar Therapeutics (NASDAQ:NKTR) was sold by Labrucherie Gil M. The insider Doberstein Stephen K sold 2,426 shares worth $201,212. The insider Thomsen Jillian B. sold $211,082.

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on May, 8. They expect $-0.43 EPS, down 2.38% or $0.01 from last year’s $-0.42 per share. After $-0.14 actual EPS reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts 207.14% negative EPS growth.

The stock increased 11.27% or $10.58 during the last trading session, reaching $104.45. About 2.86M shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 347.01% since April 10, 2017 and is uptrending. It has outperformed by 335.46% the S&P500.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Positions Chart